Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin.

Deborah E. Briggs, Caroline M. Lee, Katharyn Spiegel, Jacqueline A. French

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. METHODS: DESIGN: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed > or =2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. OUTCOME MEASURE: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio=((T-B)/(T+B))x100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. RESULTS: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P=0.0005). A lower dose of pregabalin (300mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P=0.2493). CONCLUSION: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

Original languageEnglish (US)
Pages (from-to)86-92
Number of pages7
JournalEpilepsy Research
Volume82
Issue number1
StatePublished - Nov 2008

Fingerprint

Seizures
Placebos
Pregabalin
Therapeutics
Maximum Tolerated Dose
Partial Epilepsy
Anticonvulsants
Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Briggs, D. E., Lee, C. M., Spiegel, K., & French, J. A. (2008). Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. Epilepsy Research, 82(1), 86-92.

Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. / Briggs, Deborah E.; Lee, Caroline M.; Spiegel, Katharyn; French, Jacqueline A.

In: Epilepsy Research, Vol. 82, No. 1, 11.2008, p. 86-92.

Research output: Contribution to journalArticle

Briggs, DE, Lee, CM, Spiegel, K & French, JA 2008, 'Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin.', Epilepsy Research, vol. 82, no. 1, pp. 86-92.
Briggs, Deborah E. ; Lee, Caroline M. ; Spiegel, Katharyn ; French, Jacqueline A. / Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. In: Epilepsy Research. 2008 ; Vol. 82, No. 1. pp. 86-92.
@article{a100e3507a804009afdf96c6b43c5389,
title = "Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin.",
abstract = "PURPOSE: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. METHODS: DESIGN: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed > or =2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. OUTCOME MEASURE: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio=((T-B)/(T+B))x100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. RESULTS: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P=0.0005). A lower dose of pregabalin (300mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P=0.2493). CONCLUSION: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.",
author = "Briggs, {Deborah E.} and Lee, {Caroline M.} and Katharyn Spiegel and French, {Jacqueline A.}",
year = "2008",
month = "11",
language = "English (US)",
volume = "82",
pages = "86--92",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin.

AU - Briggs, Deborah E.

AU - Lee, Caroline M.

AU - Spiegel, Katharyn

AU - French, Jacqueline A.

PY - 2008/11

Y1 - 2008/11

N2 - PURPOSE: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. METHODS: DESIGN: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed > or =2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. OUTCOME MEASURE: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio=((T-B)/(T+B))x100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. RESULTS: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P=0.0005). A lower dose of pregabalin (300mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P=0.2493). CONCLUSION: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

AB - PURPOSE: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. METHODS: DESIGN: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed > or =2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. OUTCOME MEASURE: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio=((T-B)/(T+B))x100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. RESULTS: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P=0.0005). A lower dose of pregabalin (300mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P=0.2493). CONCLUSION: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.

UR - http://www.scopus.com/inward/record.url?scp=64149132484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149132484&partnerID=8YFLogxK

M3 - Article

C2 - 18752932

AN - SCOPUS:64149132484

VL - 82

SP - 86

EP - 92

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1

ER -